These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29523055)

  • 1. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.
    Satoh Y; Nakano K; Yoshinari H; Nakayamada S; Iwata S; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Saito K; Tanaka Y
    Lupus; 2018 Jun; 27(7):1202-1206. PubMed ID: 29523055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review.
    Zhou Y; Hu Z
    Lupus; 2024 May; 33(6):644-649. PubMed ID: 38569663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab on Refractory Lupus Nephritis.
    Costa R; Antunes P; Salvador P; Oliveira P; Marinho A
    Cureus; 2021 Aug; 13(8):e17198. PubMed ID: 34540426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab (AIN457) for the treatment of psoriasis.
    López-Ferrer A; Vilarrasa E; Puig L
    Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
    Ho PH; Tsai TF
    J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab.
    Ochi M; Toyama T; Ando M; Sato K; Kamikawa Y; Sagara A; Kitajima S; Hara A; Iwata Y; Sakai N; Shimizu M; Furuichi K; Hamaguchi Y; Kaneko S; Wada T
    CEN Case Rep; 2019 Aug; 8(3):200-204. PubMed ID: 30941695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 12. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17 Blockade in Psoriasis.
    Burkett PR; Kuchroo VK
    Cell; 2016 Dec; 167(7):1669. PubMed ID: 27984714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
    Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile.
    Sato K; Aizaki Y; Yoshida Y; Mimura T
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):181-185. PubMed ID: 33086998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab in the treatment of psoriasis: an update.
    Reszke R; Szepietowski JC
    Immunotherapy; 2017 Mar; 9(3):229-238. PubMed ID: 28162025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida infections in psoriatic patients on anti-IL17 therapy: a case series.
    Papini M; Natalini Y
    J Dermatolog Treat; 2018; 29(sup2):3-4. PubMed ID: 30273067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.